A groundbreaking study has demonstrated that early screening for a severe muscle wasting disease in infants not only saves lives but also reduces healthcare costs. The call for a nationwide implementation of a simple £5 blood test for spinal muscular atrophy (SMA) by the NHS has been reinforced by research conducted at Oxford University. The study, published in the prestigious Lancet medical journal, found that since 2019, 507 babies in the UK were born with SMA, a condition that can be cured if treated immediately after birth.
In the UK, the lack of routine screening led to delayed diagnoses, with infants with the most severe form of the disease typically not being diagnosed until six months of age. This delay resulted in significant health complications, including the inability to walk, respiratory support dependency for 65% of affected infants, and the need for tube feeding in 54% of cases. Tragically, 16 infants with SMA have passed away in the UK.
Comparative research with southern Belgium, where newborn screening for SMA is standard practice, revealed that all infants identified with SMA survived and achieved better health outcomes compared to their counterparts in the UK. The study underscored the significant impact of early screening on improving the quality of life for SMA patients.
The study also highlighted the cost-effectiveness of early screening, with the average annual cost of supporting an SMA baby in the UK being significantly higher compared to babies identified through newborn screening. The findings emphasized the critical importance of implementing nationwide screening for SMA to prevent unnecessary suffering and financial burden on families and the healthcare system.
Despite the delay in implementing nationwide screening in the UK, Scotland has taken proactive steps to include SMA screening in their routine newborn testing starting this spring. The Department of Health and Social Care has acknowledged the importance of research in shaping screening policies and has committed to ensuring timely diagnosis and access to life-changing treatments for children with SMA.